Roadmap to Personalized Therapies for Sarcoma and other Aggressive Cancers

(August 8, 2017)

Sarcoma is a rare and deadly form of cancer occurring in the bones and connective tissue that affects individuals of all ages. Its aggressiveness, rarity and diversity continue to hinder efforts to identify effective therapies for people with this malignancy.... Continue Reading


SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers

(March 23, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading


Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation

(March 16, 2017)

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option.  However, a technique that limits the application of chemotherapy to the cancerous region can preserve... Continue Reading


Chemotherapy Before Surgery Improves Treatment of Sarcoma

(November 7, 2016)

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is... Continue Reading


Halaven Approved for Liposarcoma

(February 4, 2016)

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven... Continue Reading


Yondelis® Approved for Treatment of Soft Tissue Sarcoma

(November 2, 2015)

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 The approval of Yondelis is for patients whose cancer... Continue Reading


Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma

(October 20, 2015)

The chemotherapy agent, Yondelis® (trabectedine), improves outcomes compared to the standard agent, DTIC (dacarbazine), in patients with advanced liposarcoma or leiomyosarcoma that has recurred or progressed following prior therapies. These results were... Continue Reading


Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven®

(June 11, 2015)

Halaven® (eribulin) may extend overall survival in patients with previously treated, advanced soft tissue sarcoma (STS). These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois)... Continue Reading


YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

(February 4, 2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes. YONDELIS®... Continue Reading


Torisel Improves Event-Free Survival in Rhabdomyosarcoma Patients

(June 27, 2014)

In a study presented at the 2014 American Society of Clinical Oncology® meeting in Chicago, researchers reported that Torisel® (temsirolimus) added to a chemotherapy regimen improved event-free survival in young patients with rhabdomyosarcoma. Rhabdomyosarcoma... Continue Reading


Latest Sarcoma News By Stage


Ewing's Sarcoma Overview

Shorter Chemotherapy Intervals Effective in Ewing Sarcoma

(November 1, 2012)

In patients with localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than chemotherapy administered every three weeks, with no increase in toxicity, according to the results of a study published in the Journal of Clinical... Continue Reading


Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence

(February 19, 2010)

Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute. As cancer treatment has improved and evolved, the number... Continue Reading


Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence

(February 19, 2010)

Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute. As cancer treatment has improved and evolved, the number... Continue Reading


More Ewing's Sarcoma Overview

General Sarcoma

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma

(February 4, 2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes. YONDELIS®... Continue Reading


Carbon Ion Beam Radiation Effective in Spinal Sarcomas

(September 6, 2013)

Radiation therapy with carbon ions is a safe and effective treatment for people with inoperable spinal sarcomas, according to the results of a study published in Cancer. Sarcomas are a varied group of cancers arising from fibrous tissue, adipose tissue... Continue Reading


Regorafenib May Expand GIST Treatment Options

(June 13, 2012)

Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading


Votrient Approved for the Treatment of Sarcoma

(May 7, 2012)

The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first new drug in decades to treat this type of cancer. Soft... Continue Reading


Longer Treatment with Gleevec Effective Against Gastrointestinal Stromal Tumors (GIST)

(April 9, 2012)

In a Phase III clinical trial, three years of adjuvant (post-surgery) treatment with Gleevec® (imatinib) resulted in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal stromal tumors (GIST). These results... Continue Reading


More General Sarcoma

Soft Tissue Sarcomas

Chemotherapy Before Surgery Improves Treatment of Sarcoma

(November 7, 2016)

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is... Continue Reading


Halaven Approved for Liposarcoma

(February 4, 2016)

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven... Continue Reading


Yondelis® Approved for Treatment of Soft Tissue Sarcoma

(November 2, 2015)

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 The approval of Yondelis is for patients whose cancer... Continue Reading


Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma

(October 20, 2015)

The chemotherapy agent, Yondelis® (trabectedine), improves outcomes compared to the standard agent, DTIC (dacarbazine), in patients with advanced liposarcoma or leiomyosarcoma that has recurred or progressed following prior therapies. These results were... Continue Reading


Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven®

(June 11, 2015)

Halaven® (eribulin) may extend overall survival in patients with previously treated, advanced soft tissue sarcoma (STS). These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois)... Continue Reading


More Soft Tissue Sarcomas